# Ruiying Asset Management

> Ruiying Asset Management is a VC fund in Shenzhen backing Medical and Biopharma. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 3
- Last investment: Apr 2023
- Lead investor: 0%
- Last updated: Aug 2026

Ruiying Asset Management is a VC fund in Shenzhen focused on Medical and Biopharma. Ruiying Assets is an Asset Management firm

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Biopharma | 2 | 67% |
| Biotechnology | 1 | 33% |
| Medical Device | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Series A | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Boaoxin | Biosion is a biotech company focused on the development of biologics to treat resistant, relapsed, residual immune, and oncologic diseases. | $1.5K | Series B | Apr 23, 2023 |  |
| Biosun Pharma | Biosun Pharma is an innovative biopharmaceutical company that specializes in the production of drugs for tumors, self-immune diseases, and inflammatory diseases. |  | Series B | Jan 09, 2023 |  |
| Arthur Pharmaceuticals | Arthur Pharmaceuticals is a high-tech innovative pharmaceutical manufacturer. |  | Series A | Apr 06, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 1 deal together
- [Delta Capital](https://shizune.co/investors/profile/delta-capital-2) — VC Fund, 1 deal together
- [Hangzhou Yuhang Financial](https://shizune.co/investors/profile/hangzhou-yuhang-financial) — VC Fund, 1 deal together
- HMC Ventures — VC Fund, 1 deal together
- Huzhou Yuhao Equity Investment — VC Fund, 1 deal together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ruiying Asset Management invest in?

Ruiying Asset Management invests primarily in Medical, Biopharma and Biotechnology startups, most often at Series B and Series A stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ruiying Asset Management last invest?

The most recent investment recorded for Ruiying Asset Management closed in Apr 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co